drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Patient-derived T cells engineered to express a chimeric antigen receptor that targets disease-driving immune cells; CAR engagement triggers cytotoxic killing independent of the native TCR to reduce autoantibody-producing cells and restore platelet counts in ITP.
nci_thesaurus_concept_id
C200766
nci_thesaurus_definition
Autologous T-lymphocytes engineered to contain one or more chimeric antigen receptors (CARs) that specifically target one or more specific antigen(s).
drug_mesh_term
Immunotherapy, Adoptive
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor that recognizes an antigen on disease-driving immune cells; CAR engagement activates T-cell cytotoxicity independent of the native TCR, depleting autoantibody-producing cells and modulating autoimmunity to restore platelet counts in ITP.
drug_name
Autologous CAR-T cells
nct_id_drug_ref
NCT06352281